Retinal vein occlusion is the second most common vision-threatening disorder. If left untreated, it can result in vision impairment and a significant amount of other ocular complications.
The total Retinal vein occlusion prevalence in the seven major markets (i.e the US, EU5 (the UK, France, Germany, Italy, and Spain) and Japan) was 2,225,011 cases, which is further expected to increase during the study period 2017–2030.
Worldwide some of the key Retinal Vein Occlusion (RVO) companies including Novartis Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, and Outlook Therapeutics, hold huge potential to create a significant positive shift in the RVO treatment.
In the coming years owing to the emerging pipeline therapies, the rising geriatric population, an increase in disease awareness, improved health care infrastructure, technological advancements in healthcare are expected to drive the growth of the Retinal vein occlusion market forward in the coming years.
Source: Retinal Vein Occlusion Market Landscape